{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:19:26Z","timestamp":1788880766331,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      To enhance the effectiveness of radioligand therapy (RLT), new prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals utilizing alternative radionuclides are under active investigation. One promising alternative to the established\n                      <jats:sup>177<\/jats:sup>\n                      Lu is the use of\n                      <jats:sup>161<\/jats:sup>\n                      Tb. A key advantage of\n                      <jats:sup>161<\/jats:sup>\n                      Tb is its emission of a higher proportion of low-energy conversion and Auger electrons, which may contribute to enhanced therapeutic effectiveness. This study provides a first exploratory evaluation of the efficacy and safety of [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617 in patients with progression after [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617, aiming to generate early clinical insights.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The study included 15 patients with mCRPC, who were enrolled in the \u201cprospective registry to assess outcome and toxicity of targeted radionuclide therapy in patients with mCRPC in clinical routine\u201c (REALITY Study; NCT04833517). All patients had received conventional PSMA RLT using [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617, which resulted in initial biochemical response (PSA decline \u226550%), followed by a biochemical relapse, prompting the re-initiation of PSMA RLT using [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617. Patients received a median of 3 (range: 2\u20137) cycles with mean administered activity of 5.4 \u00b1 1.1 GBq and mean cumulative activity of 19.2 \u00b1 6.4 GBq [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617. Treatment response was assessed both biochemically by serum PSA levels and through molecular imaging by total lesion PSMA (TLP) on [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 PET\/CT scans. Adverse events were assessed at baseline and follow-up using the \u201cCommon Terminology Criteria for Adverse Events\u201c (Version 5.0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617 RLT showed response rates of 66.7% (10\/15 patients) based on biochemical assessment and 86.7% (13\/15 patients) based on molecular imaging assessment. Beginning with the initiation of [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617 RLT, the median progression-free survival (PFS) was 6.4 months, and the median overall survival (OS) was 15.5 months. In total, 6 CTCAE grade deteriorations from grade 2 to grade 3 or from grade 3 to grade 4 were observed. No discontinuation of PSMA RLT due to adverse events was reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>161<\/jats:sup>\n                      Tb]Tb-PSMA-617 RLT emerges as a promising treatment option, demonstrating encouraging response rates, preliminary clinical outcomes, and a favorable safety profile as second-line RLT in progressing patients who previously benefited from [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 RLT.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006384","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:02:46Z","timestamp":1777903366000},"page":"e356-e361","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Outcome and Safety of Radioligand Therapy With [161Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177Lu]Lu-PSMA-617"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-4099","authenticated-orcid":false,"given":"Florian","family":"Rosar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-8860","authenticated-orcid":false,"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Phuong Thao","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2106-9548","authenticated-orcid":false,"given":"Moritz B.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Speicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-5786","authenticated-orcid":false,"given":"Andrea","family":"Schaefer-Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-3375","authenticated-orcid":false,"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-0043-1774733","article-title":"Theranostics in developing countries: addressing challenges and potentials from training to practice","volume":"22","author":"Al-Ibraheem","year":"2023","journal-title":"World J Nucl Med"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11523-021-00801-w","article-title":"Real-world data analysis of efficacy and survival after lutetium-177 labelled PSMA ligand therapy in metastatic castration-resistant prostate cancer","volume":"16","author":"Meyrick","year":"2021","journal-title":"Target Oncol"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00259-024-06825-4","article-title":"Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)","volume":"51","author":"Rosar","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.118.215715","article-title":"Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00259-018-4222-x","article-title":"Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer","volume":"46","author":"Yordanova","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2967\/jnumed.119.236414","article-title":"Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J Nucl Med"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy","volume":"57","author":"Hindi\u00e9","year":"2016","journal-title":"J Nucl Med"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.7150\/thno.92273","article-title":"[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s13139-024-00891-0","article-title":"Harnessing terbium radioisotopes for clinical advancements: a systematic review","volume":"59","author":"Abdlkadir","year":"2025","journal-title":"Nucl Med Mol Imaging"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"108998","DOI":"10.1016\/j.nucmedbio.2025.108998","article-title":"Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177","volume":"144\u2013145","author":"Trejtnar","year":"2025","journal-title":"Nucl Med Biol"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"key":"R27-20260504","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.7150\/thno.115831","article-title":"Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry","volume":"15","author":"Rosar","year":"2025","journal-title":"Theranostics"},{"key":"R28-20260504","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"R29-20260504","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00259-023-06476-x","article-title":"Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry","volume":"51","author":"Burgard","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R30-20260504","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R31-20260504","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2967\/jnumed.120.258376","article-title":"First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med"},{"key":"R32-20260504","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s13139-023-00804-7","article-title":"161Tb-PSMA unleashed: a promising new player in the theranostics of prostate cancer","volume":"57","author":"Al-Ibraheem","year":"2023","journal-title":"Nucl Med Mol Imaging"},{"key":"R33-20260504","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/RLU.0000000000004589","article-title":"New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC","volume":"48","author":"Rosar","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R34-20260504","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.123.267321","article-title":"Safety and efficacy of extended therapy with [177Lu]Lu-PSMA: a German multicenter study","volume":"65","author":"Seifert","year":"2024","journal-title":"J Nucl Med"},{"key":"R35-20260504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases","volume":"7","author":"Alcocer-\u00c1vila","year":"2020","journal-title":"EJNMMI Phys"},{"key":"R36-20260504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","article-title":"Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection","volume":"10","author":"Verburg","year":"2023","journal-title":"EJNMMI Phys"},{"key":"R37-20260504","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/RLU.0000000000004589","article-title":"New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC","volume":"48","author":"Rosar","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R38-20260504","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R39-20260504","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"R40-20260504","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1097\/RLU.0000000000005640","article-title":"225Ac-PSMA-617 augmentation after insufficient response under 177Lu-PSMA-617 radioligand therapy in mCRPC: evaluation of outcome and safety from a prospective registry (REALITY Study)","volume":"50","author":"Rosar","year":"2025","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:01:07Z","timestamp":1777921267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006384","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}